Gastrointestinal inflammation, such as occurs in inflammatory bowel disease, triggers the expansion of a population of “bone-eating” cells, leading to bone loss.

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

A probiotic factor given early in life to mice prevented intestinal inflammation in adulthood, providing a rationale for probiotic intervention in individuals at high risk of developing inflammatory bowel disease.

The new Endoscopy Lab at One Hundred Oaks has expanded Vanderbilt Health’s options for endoscopic procedures including colonoscopies to screen for colorectal cancer.

A selenium transport protein produced in the colon may be a novel biomarker for assessing disease severity and cancer risk in patients with inflammatory bowel disease.

VUMC has been awarded a three-year, $3 million grant to map — in unprecedented detail — the biology of Crohn’s disease.

Vanderbilt investigators demonstrated that intestinal cells promote beneficial microbe behavior — the findings support developing microbiota-based therapies for intestinal health.